- Corporate Governance
- Features & Analyses
- Foreign Direct Investment
- Retail Trade and Distribution
- Technology Media and Telecom
Regulatory Developments in the China Pharmaceutical and Medtech Sector in 2024, and the Outlook for 2025
Chinese regulatory support to China originated-biopharma companies is going global. Wu Ting, partner of the Life Sciences and Healthcare Practice at Haiwen & Partners examines the implications
Share:
Summary
- As the sector makes the transition from creative limitation to genuine innovation
- Harmonization was another key theme, in order to facilitate both "coming in" and "going out"
- 2024 was